ERBB2 and neoplasm: Further understanding of HER2 heterogeneity within a tumor can be important to predict response to anti-HER2 targeted therapies, guide treatment decision, improve clinical outcomes and shed light on development of novel anti-HER2 agents to overcome resistance.